While native EPO exerts both hematopoietic and tissue-protective effects via erythropoietin receptor (EPOR) homodimer activation [177,178], its clinical use beyond anemia is limited by adverse effects related to increased red blood cell production [179,180,181]. This evidence concerns the gene EPOR and anemia.